Julie Vose, MD
Enriched profileDirector, Lymphoma Research Group, Armitage Center for Hematologic Malignancy Research; George and Peggy Payne Distinguished Chair of Oncology; Professor, Division of Hematology/Oncology, UNMC · University of Nebraska Medical Center
Julie Vose is Director, Lymphoma Research Group, Armitage Center for Hematologic Malignancy Research; George and Peggy Payne Distinguished Chair of Oncology; Professor, Division of Hematology/Oncology, UNMC at University of Nebraska Medical Center. OpenAlex indexes 903 publications with 59,133 citations (h-index 111); ClinicalTrials.gov lists 32 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 5% of Hematology / Oncology profiles in the findmyKOL directory.
Data verified 14 Aug 2026
Overview
Updated 14 Oct 2026
Julie Vose, MD, is Director, Lymphoma Research Group, Armitage Center for Hematologic Malignancy Research at University of Nebraska Medical Center / Nebraska Medicine (Fred & Pamela Buffett Cancer Center). The public record shows 903 publications with 59,133 citations (h-index 111), centered on Lymphoma Diagnosis and Treatment, Chronic Lymphocytic Leukemia Research, CAR-T cell therapy research. It also documents an investigator role on 32 registered clinical trials, industry payments reported by 24 companies, 4 NIH-funded awards (1993–2016).
- Top research focus: Lymphoma Diagnosis and Treatment
- 32 registered trials on ClinicalTrials.gov
- Open Payments reporting from 24 companies
Generated from the cited public record · current as of 14 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 35 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 401.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 14 Oct 2026
Listed as an investigator on 32 registered studies on ClinicalTrials.gov. The most recent:
- MB-105 in Patients With CD5 Positive T-cell Lymphoma
Sponsor: March Biosciences Inc
- Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma
Sponsor: Alliance for Clinical Trials in Oncology
- CAR-T Followed by Bispecific Antibodies
Sponsor: Abramson Cancer Center at Penn Medicine
Industry payments
Updated 14 Oct 2026
24 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Genentech USA, Inc.Program year20251 payment
- BeOne Medicines USA, Inc.Program year20252 payments
- KYOWA KIRIN, INC.Program year20251 payment
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
37.2%Kinase inhibitor27.7%Brukinsa45%Imbruvica29%Calquence19%Jaypirca7%Part D<11 patientsBCL-2 Inhibitor7.9%Venclexta100%Part D<11 patients+ 1 more class in this area
Metabolism & gastrointestinal
23.2%Corticosteroid13%Prednisone100%Part D≥27 patientsSerotonin-3 Receptor Antagonist7.1%Ondansetron Odt52%Ondansetron Hcl48%Part D≥18 patients+ 1 more class in this area
Anti-infectives
13%Short-acting sulfonamides13%Sulfamethoxazole-Trimethoprim100%Part D≥33 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 14 Oct 2026
4 NIH research awards on record, funded 1993–2016 per NIH RePORTER. The latest:
- Nebraska/Kansas Blood and Marrow Transplant Research Network
University of Nebraska Medical Center
FY2016$154,372U10HL069233 - Nebraska/Kansas Blood and Marrow Transplant Research Network
University of Nebraska Medical Center
FY2015$154,372U10HL069233 - FLT-PET/CT for Therapy Monitoring of DLBCL
University of California Los Angeles
FY2014$311,891R01CA152923
Congress activity
Updated 14 Oct 2026
115 congress contributions (1993–2025) across AACR, ASCO, ASH, ASTRO, ESMO per OpenAlex. The most recent:
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Most-cited works
by citation count (OpenAlex)- 01Revised Response Criteria for Malignant LymphomaArticle4,455 citations2007
- 02The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell LymphomaArticle3,866 citations2002
- 03Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's LymphomasArticle3,493 citations1999
- 04
- 05
Network
Updated 14 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 14 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/julie-vose-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - LinkedIn
linkedin.com/in/julie-vose-2407ba7
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗ - LinkedIn
linkedin.com/in/julie-vose-b76b49380
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗ - X / Twitter
x.com/DrJulieVose
Mentions by others
where others cite or feature them- Other
society.asco.org/people/julie-vose-md-mba-fasco
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →society.asco.org ↗ - Other
unmc.edu/newsroom/2025/10/01/julie-vose-md-to-assume-new-leadership-role-in-lymphoma-research
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →unmc.edu ↗ - YouTube
youtube.com/watch
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com ↗ - YouTube
youtube.com/watch
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 14 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →unmc.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →unmc.edu ↗
- Board Certified
Hematology
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →nebraskamed.com ↗ - Board Certified
Medical Oncology
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →nebraskamed.com ↗
Editorial & leadership roles
journal and society appointments- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →unmc.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →unmc.edu ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ascopost.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →unmc.edu ↗
- Co-Editor-in-Chief
ONCOLOGY journal (CancerNetwork)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancernetwork.com ↗ - Fellow
American Society of Clinical Oncology (FASCO)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →expertperspectives.com ↗
Media & interviews
press, podcasts and appearances- "Get to Know ... Julie Vose, MD, MBA" feature interview
Blood Cancers Today
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →bloodcancerstoday.com ↗ - provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com ↗
- "An interview with Julie Vose: where is oncology heading?" published interview
PubMed/Future Oncology
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →pubmed.ncbi.nlm.nih.gov ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Kathleen Moore, MD
University of Nebraska Medical Center
Ted Mikuls, MD
University of Nebraska Medical Center
Roslyn Mannon, MD
University of Nebraska Medical Center
James Armitage, MD
University of Nebraska Medical Center
Seth Steinberg, PhD
National Cancer Institute (NCI)
Gilles Salles
Memorial Sloan Kettering Cancer Center
Wyndham Wilson, MD
National Cancer Institute (NCI)
Anne Tsao, MD
The University of Texas MD Anderson Cancer Center